Strs Ohio Cuts Stake in Teva Pharmaceutical Industries Ltd. $TEVA

Key Points

• STRS Ohio cut its Teva stake by 25.7% in Q4, selling 196,346 shares and ending the period with 566,561 shares valued at about $17.68 million.
• Large institutions including Phoenix Financial, Menora Mivtachim, Harel and Migdal materially increased positions—institutional ownership is 54.05%—and investor sentiment is supported by a Q1 earnings beat, multiple broker upgrades and Teva’s ~\$900M agreement to acquire Emalex, which bolsters its branded‑product growth narrative.
• Despite positive analyst momentum (consensus "Moderate Buy", average target \$41.56), insiders have sold heavily recently (920,901 shares worth roughly \$30M over three months), while the stock trades near its 52‑week high with a market cap of \$40.24B and a P/E of 26.31.

Strs Ohio cut its holdings in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 25.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 566,561 shares of the company's stock after selling 196,346 shares during the period. Strs Ohio's holdings in Teva Pharmaceutical Industries were worth $17,682,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of the business. Phoenix Financial Ltd. boosted its position in shares of Teva Pharmaceutical Industries by 9.4% during the third quarter. Phoenix Financial Ltd. now owns 41,295,244 shares of the company's stock valued at $834,164,000 after buying an additional 3,533,800 shares during the last quarter. Menora Mivtachim Holdings LTD. boosted its position in shares of Teva Pharmaceutical Industries by 1.1% during the third quarter. Menora Mivtachim Holdings LTD. now owns 38,920,294 shares of the company's stock valued at $786,190,000 after buying an additional 427,000 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. boosted its position in shares of Teva Pharmaceutical Industries by 12.9% during the third quarter. Harel Insurance Investments & Financial Services Ltd. now owns 37,696,690 shares of the company's stock valued at $761,455,000 after buying an additional 4,306,363 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. boosted its position in shares of Teva Pharmaceutical Industries by 14.8% during the fourth quarter. Migdal Insurance & Financial Holdings Ltd. now owns 37,402,212 shares of the company's stock valued at $1,167,323,000 after buying an additional 4,820,000 shares during the last quarter. Finally, Rubric Capital Management LP boosted its position in shares of Teva Pharmaceutical Industries by 1.8% during the second quarter. Rubric Capital Management LP now owns 26,000,000 shares of the company's stock valued at $435,760,000 after buying an additional 450,000 shares during the last quarter. 54.05% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Teva Pharmaceutical Industries

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Q1 earnings beat and revenue upside driven by branded products (Austedo, Ajovy, Uzedy), which lifted investor sentiment and underpins near‑term earnings growth. Read More.
• Positive Sentiment: Multiple broker upgrades and higher price targets — UBS, Truist, JPMorgan and Piper Sandler raised targets/ratings over the last day, signaling analyst confidence in a re‑rating and further upside for the stock. Read More. Read More.
• Positive Sentiment: Teva agreed to acquire Emalex for ~\$900M to add ecopipam (paediatric Tourette’s) — a late‑stage, de‑risked asset that bolsters the specialty/innovative portfolio and supports the narrative that Teva is shifting toward higher‑margin branded growth. Read More.
• Neutral Sentiment: Teva published its 2025 Healthy Future Report and says it met all sustainability‑linked bond targets — positive for ESG profile and potentially credit metrics, but unlikely to move near‑term revenues. Read More.
• Neutral Sentiment: Blackstone put significant financing behind Teva in a recent deal — signals institutional interest/validation but primarily affects capital structure and optionality rather than immediate EPS. Read More.
• Neutral Sentiment: Industry reports list Teva among leaders in oral solid dosage contract manufacturing — positive for long‑term service demand exposure but not an immediate earnings catalyst. Read More.
• Negative Sentiment: Generics revenue remains weak even as branded sales grow — raises questions about sustainability of overall top‑line growth if branded momentum slows. Read More.
• Negative Sentiment: After a rapid share run‑up, some analysts and coverage pieces note valuation/volatility risk — investors should weigh near‑term upside from upgrades against stretched multiples and execution risk. Read More.

Teva Pharmaceutical Industries Stock Up 0.1%

TEVA stock opened at $35.00 on Monday. Teva Pharmaceutical Industries Ltd. has a fifty-two week low of $14.99 and a fifty-two week high of $37.35. The business's 50-day moving average is $31.15 and its two-hundred day moving average is $29.46. The company has a debt-to-equity ratio of 1.70, a quick ratio of 0.78 and a current ratio of 1.01. The company has a market cap of $40.24 billion, a price-to-earnings ratio of 26.31, a P/E/G ratio of 3.23 and a beta of 0.86.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its earnings results on Tuesday, March 31st. The company reported $0.53 earnings per share for the quarter. Teva Pharmaceutical Industries had a return on equity of 43.53% and a net margin of 9.01%.The company had revenue of $3.98 billion for the quarter. As a group, analysts forecast that Teva Pharmaceutical Industries Ltd. will post 2.6 earnings per share for the current year.

Insider Transactions at Teva Pharmaceutical Industries

In other news, insider Placid Jover sold 14,150 shares of the firm's stock in a transaction dated Thursday, March 5th. The stock was sold at an average price of $31.67, for a total value of $448,130.50. Following the transaction, the insider owned 6,774 shares of the company's stock, valued at $214,532.58. This trade represents a 67.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Richard Daniell sold 17,295 shares of the firm's stock in a transaction dated Thursday, March 5th. The stock was sold at an average price of $31.67, for a total value of $547,732.65. Following the completion of the transaction, the executive vice president directly owned 85,755 shares in the company, valued at $2,715,860.85. This trade represents a 16.78% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 920,901 shares of company stock valued at $30,056,789. Company insiders own 0.54% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts recently commented on the company. Truist Financial increased their price objective on Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the company a "buy" rating in a research report on Thursday. Barclays increased their price objective on Teva Pharmaceutical Industries from $35.00 to $38.00 and gave the company an "overweight" rating in a research report on Friday, January 30th. The Goldman Sachs Group increased their price objective on Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the company a "buy" rating in a research report on Monday, February 9th. Bank of America increased their price objective on Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the company a "buy" rating in a research report on Thursday, April 9th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Teva Pharmaceutical Industries in a report on Monday, April 20th. Nine investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Teva Pharmaceutical Industries currently has a consensus rating of "Moderate Buy" and an average target price of $41.56.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. NYSE: TEVA is an Israeli multinational pharmaceutical company and one of the world's largest manufacturers of generic medicines. The company's core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva's product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.